CDTX
$1.43
Cidara Thera
($.47)
(24.74%)
CDTX
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus:  ($0.01)
Revenue:  $10.57 Mil
Thursday
Mar 23
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CDTX reports earnings?
Beat
Meet
Miss

Where is CDTX's stock price going from here?
Up
Flat
Down
Stock chart of CDTX
Analysts
Summary of analysts' recommendations for CDTX
Score
Grade
Pivots
Resistance
$2.07
$1.90
$1.66

$1.49

Support
$1.25
$1.08
$0.84
Tweet
Growth
Description
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
›